Elucidation of drug resistance of Wnt5a positive breast cancer and its application to anticancer therapy
| Project/Area Number |
26861049
|
|---|
| Research Category |
Grant-in-Aid for Young Scientists (B)
|
| Allocation Type | Multi-year Fund |
|---|
| Research Field |
General surgery
|
|---|
| Research Institution | Hiroshima University |
|---|
Principal Investigator |
|
|---|
| Project Period (FY) |
2014-04-01 – 2017-03-31
|
| Project Status |
Completed (Fiscal Year 2016)
|
| Budget Amount *help |
¥3,640,000 (Direct Cost: ¥2,800,000、Indirect Cost: ¥840,000)
Fiscal Year 2016: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2015: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2014: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
|
|---|
| Keywords | Wnt5a / 分子標的治療 / Wint5a / 乳癌 / 治療 / 薬剤感受性 |
|---|
| Outline of Final Research Achievements |
Relationships were examined between Wnt5a expression and clinicopathologic factors in 178 consecutive cases of invasive breast cancer.(1)Wnt5a was positively expressed in 69 cases (39%) among 178 cases of invasive breast cancer. Wnt5a expression was strongly correlated with being estrogen receptor (ER)-positive.(2)Analysis of the relationship between Wnt5a expression and malignancy in exclusively 153 cases of ER-positive breast cancer led to detection of significant correlations with lymph node metastasis, nuclear grade, and lymphatic invasion. (3)Relapse-free survival was shorter in cases of Wnt5a-positive breast cancer compared to Wnt5a-negative breast cancer cases. Base on our data, Wnt5a expression can be a prognostic factor in ER-positive breast cancer.
|
Report
(4 results)
Research Products
(5 results)
